3 independent, multicenter, prospective, signel-arm phase II trial, based on 2-stage Simon's optimal design, will be conducted in parallel to assess the efficacy of pembrolizumab + cabozantinib, in distinct populations of sarcomas:~stratum 1: advanced undiffenrentiated pleomorphic sarcoma~stratum 2: advanced osteosarcoma~stratum 3: advanced ewing sarcoma
Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.